These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
348 related articles for article (PubMed ID: 36301892)
1. Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk. Katzmann JL; Becker C; Bilitou A; Laufs U PLoS One; 2022; 17(10):e0276898. PubMed ID: 36301892 [TBL] [Abstract][Full Text] [Related]
2. Simulation of lipid-lowering therapy (LLT) intensification in very high-risk patients with atherosclerotic cardiovascular disease. Gu J; Sanchez RJ; Chauhan A; Fazio S; Rosenson RS J Clin Lipidol; 2022; 16(6):901-905. PubMed ID: 36319536 [TBL] [Abstract][Full Text] [Related]
3. Patients With High Cardiovascular Risk as Candidates to Bempedoic Acid, After Treatment With Statins, Ezetimibe and PCSK9 Inhibitors: An Estimation and Cost-Effectiveness Analysis. Seijas-Amigo J; Cordero A; Olmo RF; Cortez Quiroga GA; Fácila L; Salgado-Barreira Á; Reyes-Santías F; Romero-Menor C; Murillo JR; Rodríguez-Mañero M; Bello Mora MC; Valle A; Sandin M; Pamias RF; Bañeras J; García PB; Lorenzo MC; Sánchez-Alvarez S; López-Rodríguez L; González-Juanatey JR J Cardiovasc Pharmacol; 2023 Jan; 81(1):70-75. PubMed ID: 36219195 [TBL] [Abstract][Full Text] [Related]
4. The therapeutic management of South African dyslipidaemic patients at very high cardiovascular risk (CARDIO TRACK): a cross-sectional study. Blom DJ; Ranjith N; Joshi P; Naidoo P; van Tonder A; Musa MG; Joshi S; Leisegang R; Trokis JS; Makan H; Raal FJ Cardiovasc J Afr; 2020; 31(5):245-251. PubMed ID: 33151240 [TBL] [Abstract][Full Text] [Related]
5. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations. Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N BMJ; 2022 May; 377():e069066. PubMed ID: 35508320 [TBL] [Abstract][Full Text] [Related]
6. Target Populations and Treatment Cost for Bempedoic Acid and PCSK9 Inhibitors: A Simulation Study in a Contemporary CAD Cohort. Blaum C; Brunner FJ; Goßling A; Kröger F; Bay B; Lorenz T; Graef A; Zeller T; Schnabel R; Clemmensen P; Westermann D; Blankenberg S; Seiffert M; Waldeyer C Clin Ther; 2021 Sep; 43(9):1583-1600. PubMed ID: 34462126 [TBL] [Abstract][Full Text] [Related]
7. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease. Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335 [TBL] [Abstract][Full Text] [Related]
8. [Hypercholesterolemia and cardiovascular risk]. Sinning D; Landmesser U Dtsch Med Wochenschr; 2023 Aug; 148(16):1025-1032. PubMed ID: 37541292 [TBL] [Abstract][Full Text] [Related]
9. Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients. Toplak H; Bilitou A; Alber H; Auer J; Clodi M; Ebenbichler C; Fließer-Görzer E; Gelsinger C; Hanusch U; Ludvik B; Maca T; Schober A; Sock R; Speidl WS; Stulnig TM; Weitgasser R; Zirlik A; Koch M; Wienerroither S; Wolowacz SE; Diamand F; Catapano AL Wien Klin Wochenschr; 2023 Jul; 135(13-14):364-374. PubMed ID: 37286910 [TBL] [Abstract][Full Text] [Related]
10. Intensive lipid-lowering therapy for early achievement of guideline-recommended LDL-cholesterol levels in patients with ST-elevation myocardial infarction ("Jena auf Ziel"). Makhmudova U; Samadifar B; Maloku A; Haxhikadrija P; Geiling JA; Römer R; Lauer B; Möbius-Winkler S; Otto S; Schulze PC; Weingärtner O Clin Res Cardiol; 2023 Sep; 112(9):1212-1219. PubMed ID: 36602598 [TBL] [Abstract][Full Text] [Related]
11. The need for PCSK9 inhibitors and associated treatment costs according to the 2019 ESC dyslipidaemia guidelines vs. the risk-based allocation algorithm of the 2017 ESC consensus statement: a simulation study in a contemporary CAD cohort. Blaum C; Seiffert M; Goßling A; Kröger F; Bay B; Lorenz T; Braetz J; Graef A; Zeller T; Schnabel R; Clemmensen P; Westermann D; Blankenberg S; Brunner FJ; Waldeyer C Eur J Prev Cardiol; 2021 Mar; 28(1):47-56. PubMed ID: 33580772 [TBL] [Abstract][Full Text] [Related]
12. An estimation of the consequences of reinforcing the 2016 and 2019 European Society of Cardiology/European Atherosclerosis Society guidelines on current lipid-lowering treatment in patients with type 2 diabetes in tertiary care-a SwissDiab study. Singeisen H; Renström F; Laimer M; Lehmann R; Bilz S; Brändle M Eur J Prev Cardiol; 2023 Oct; 30(14):1473-1481. PubMed ID: 37226890 [TBL] [Abstract][Full Text] [Related]
13. [Modern lipid-lowering drugs-A means to counter the problem of undertreatment?]. Katzmann JL; Laufs U Inn Med (Heidelb); 2022 Dec; 63(12):1316-1322. PubMed ID: 35391570 [TBL] [Abstract][Full Text] [Related]
14. Potential Cardiovascular Events Avoided with Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared with Ezetimibe Alone in Patients with Atherosclerotic Cardiovascular Disease Taking Maximally Tolerated Statins. McQueen RB; Baum SJ; Louie MJ; Sasiela WJ; Bilitou A; Shah H; Nash B; Gillard KK; Ray KK Am J Cardiovasc Drugs; 2023 Jan; 23(1):67-76. PubMed ID: 36316612 [TBL] [Abstract][Full Text] [Related]
15. LDL cholesterol target attainment in cardiovascular high- and very-high-risk patients with statin intolerance: a simulation study. Katzmann JL; Stürzebecher PE; Kruppert S; Laufs U Sci Rep; 2024 Jan; 14(1):474. PubMed ID: 38172531 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159 [TBL] [Abstract][Full Text] [Related]
17. Bempedoic acid in the management of lipid disorders and cardiovascular risk. 2023 position paper of the International Lipid Expert Panel (ILEP). Banach M; Penson PE; Farnier M; Fras Z; Latkovskis G; Laufs U; Paneni F; Parini P; Pirro M; Reiner Ž; Vrablik M; Escobar C Prog Cardiovasc Dis; 2023; 79():2-11. PubMed ID: 36889490 [TBL] [Abstract][Full Text] [Related]